Study of Escitalopram in the Treatment of Specific Phobia

Connor, Kathryn M., M.D.

Status and phase

Completed

Phase 3

Phase 2

Conditions

Phobic Disorders

Treatments

Drug: Escitalopram

Study type

Interventional

Funder types

Industry

Identifiers

NCT00121069

3990-02-9

Details and patient eligibility

About

This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.

Full description

This double-blind placebo-controlled pilot trial study is designed to assess the efficacy of 12 weeks of escitalopram vs. placebo in the treatment of specific phobia in adult outpatients. It is hypothesized that escitalopram is safe and effective in the treatment of specific phobia.

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Adults 18-65 years of age
DSM-IV criteria for specific phobia according to the MINI
For women of childbearing potential, a negative serum pregnancy test at screening
Written informed consent

Exclusion criteria

Any current primary DSM-IV diagnosis other than specific phobia
History of DSM-IV substance abuse or dependence within the last months
Lifetime history of bipolar I disorder, schizophrenia or other psychotic disorder, mental retardation, or other pervasive developmental disorder or cognitive disorder due to a general medical condition
Suicide risk or serious suicide attempt within the last year
Clinically significant laboratory or EKG abnormality or unstable medical condition
For women of childbearing potential, unwillingness to use an acceptable form of contraception during the study
Subjects needing concurrent use of psychotropic medications